chronic lymphocytic leukemia/small lymphocytic lymphoma
chronic lymphocytic leukemia/small lymphocytic lymphoma
Explore linked clinical trials. Standard reference: MONDO:000386425 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL | chronic lymphocytic leukemia/small lymphocytic lymphoma | Recruiting | Phase 1 / Phase 2 | 2026-10-05 | NCT05791409 | |
| Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic lymphocytic leukemia/small lymphocytic lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-09-28 | NCT07685717 | |
| REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) | chronic lymphocytic leukemia/small lymphocytic lymphoma | Recruiting | Phase 2 | 2026-09-21 | NCT04523428 | |
| Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Richter transformation, Waldenstrom macroglobulinemia, cardiovascular disorder, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, marginal zone lymphoma, monoclonal gammopathy, neoplasm, non-Hodgkin lymphoma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 / Phase 2 | 2026-08-21 | NCT05294731 | |
| A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. | chronic lymphocytic leukemia/small lymphocytic lymphoma | Recruiting | Phase 3 | 2026-07-28 | NCT06319456 | |
| Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, immune system disorder, immunoproliferative disorder, indolent B-cell non-Hodgkin lymphoma, large B-cell lymphoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm, non-Hodgkin lymphoma | Active, not recruiting | Phase 1 | 2026-07-10 | NCT05665062 | |
| A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic lymphocytic leukemia/small lymphocytic lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-06-22 | NCT07154264 | |
| Global Trial in APG2575 for Patients With CLL/SLL | chronic lymphocytic leukemia/small lymphocytic lymphoma | Recruiting | Phase 3 | 2026-06-18 | NCT06104566 | |
| A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic lymphocytic leukemia/small lymphocytic lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2026-06-03 | NCT07139873 | |
| DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8) | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic lymphocytic leukemia/small lymphocytic lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-06-02 | NCT06539182 | |
| Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic lymphocytic leukemia/small lymphocytic lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-05-14 | NCT04458610 | |
| Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic lymphocytic leukemia/small lymphocytic lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Phase 2 | 2026-05-12 | NCT07582159 | |
| Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, anemia, autoimmune disease, autoimmune hemolytic anemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, hematologic disorder, hemolytic anemia, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-05-06 | NCT04657094 | |
| Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Recruiting | Phase 1 | 2026-04-20 | NCT06859008 | |
| The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic lymphocytic leukemia/small lymphocytic lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Not applicable | 2026-04-09 | NCT05876923 | |
| Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. | B-cell neoplasm, Blood Protein Disorders, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Waldenstrom macroglobulinemia, cardiovascular disorder, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, hairy cell leukemia, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, marginal zone lymphoma, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2026-02-13 | NCT04775745 | |
| Study of Epcoritamab as a Consolidation Therapy in CLL/SLL | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic lymphocytic leukemia/small lymphocytic lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-01-06 | NCT07108998 | |
| Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic lymphocytic leukemia/small lymphocytic lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2025-12-16 | NCT06757647 | |
| French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings | chronic lymphocytic leukemia/small lymphocytic lymphoma | Active, not recruiting | Not stated | 2025-12-03 | NCT05590702 | |
| Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors | Arrhythmias, Cardiac, B-cell chronic lymphocytic leukemia, Blood Protein Disorders, Chronic Disease, Death, Death, Sudden, Death, Sudden, Cardiac, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Waldenstrom macroglobulinemia, atrial fibrillation, cardiac arrest, cardiovascular disorder, chronic lymphocytic leukemia/small lymphocytic lymphoma, heart disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Not applicable | 2025-09-18 | NCT05643235 | |
| LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic lymphocytic leukemia/small lymphocytic lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2025-08-14 | NCT06978088 | |
| Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL | chronic lymphocytic leukemia/small lymphocytic lymphoma | Recruiting | Phase 1 | 2025-04-10 | NCT04215809 | |
| A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy | chronic lymphocytic leukemia/small lymphocytic lymphoma | Not yet recruiting | Phase 2 | 2024-06-27 | NCT06476899 | |
| (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Richter transformation, T-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm | Not yet recruiting | Not stated | 2023-10-23 | NCT05923502 | |
| Clinical Study of Orelabrutinib Combined With BG Regimen First-line Treatment of CLL/SLL | chronic lymphocytic leukemia/small lymphocytic lymphoma | Not yet recruiting | Phase 2 | 2023-06-26 | NCT05918276 |